A phase I/II study of intravenous gemcitabine and nab-paclitaxel combined with intraperitoneal paclitaxel in pancreatic cancer patients with peritoneal metastasis
Phase 1
- Conditions
- pancreatic cancer patients with peritoneal metastasis
- Registration Number
- JPRN-UMIN000024148
- Lead Sponsor
- Department of Gastroenterology, The University of Tokyo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 53
Inclusion Criteria
Not provided
Exclusion Criteria
1) contraindication for gemcitabine, nab-paclitaxel or paclitaxel 2) other active concomitant malignancies 3) allergy to iodine or gadolinium contrast agent 4) Blood transfusion or usege of G-CSF within 7 days before enrollment 5) past or current severe heart disease, liver cirrhosis, active GI ulcers or obstruction 6) severe complications such as interstitial pneumonitis, pulmonary fibrosis 7) uncontrollable diabetes mellitus 8) grade 3/4 of sensory neuropathy 9) active infection rather than HBV/HCV 11) pregnant or nursing women 12) judged to be unfit to participate in this study by investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method